Mechanism of Action of Non-coding RNAs and Traditional Chinese Medicine in Myocardial Fibrosis: Focus on the TGF-β/Smad Signaling Pathway

Overview

Journal Front Pharmacol

Date 2023 Feb 27

PMID 36843918

Authors

Chunjun Li

Xiangxiang Meng

Lina Wang

Xia Dai

Affiliations

Soon will be listed here.

Abstract

Cardiac fibrosis is a serious public health problem worldwide that is closely linked to progression of many cardiovascular diseases (CVDs) and adversely affects both the disease process and clinical prognosis. Numerous studies have shown that the TGF-β/Smad signaling pathway plays a key role in the progression of cardiac fibrosis. Therefore, targeted inhibition of the TGF-β/Smad signaling pathway may be a therapeutic measure for cardiac fibrosis. Currently, as the investigation on non-coding RNAs (ncRNAs) move forward, a variety of ncRNAs targeting TGF-β and its downstream Smad proteins have attracted high attention. Besides, Traditional Chinese Medicine (TCM) has been widely used in treating the cardiac fibrosis. As more and more molecular mechanisms of natural products, herbal formulas, and proprietary Chinese medicines are revealed, TCM has been proven to act on cardiac fibrosis by modulating multiple targets and signaling pathways, especially the TGF-β/Smad. Therefore, this work summarizes the roles of TGF-β/Smad classical and non-classical signaling pathways in the cardiac fibrosis, and discusses the recent research advances in ncRNAs targeting the TGF-β/Smad signaling pathway and TCM against cardiac fibrosis. It is hoped, in this way, to give new insights into the prevention and treatment of cardiac fibrosis.

Citing Articles

Chitosan-Artesunate nanoparticles: A dual anti-fibrotic and anti-inflammatory strategy for preventing bleb fibrosis post-glaucoma filtration surgery.

Liu J, Wang S, Tan G, Tong B, Wu Y, Zhang L Drug Deliv Transl Res. 2025; .

PMID: 40019651 DOI: 10.1007/s13346-025-01819-7.

Baricitinib represses the myocardial fibrosis via blocking JAK/STAT and TGF-β1 pathways in vivo and in vitro.

Feng R, Liu H, Chen Y BMC Cardiovasc Disord. 2025; 25(1):65.

PMID: 39891042 PMC: 11783835. DOI: 10.1186/s12872-025-04517-x.

Association between Inflammation and New-Onset Atrial Fibrillation in Acute Coronary Syndromes.

Baghina R, Crisan S, Luca S, Patru O, Lazar M, Vacarescu C J Clin Med. 2024; 13(17).

PMID: 39274304 PMC: 11396258. DOI: 10.3390/jcm13175088.

Antifibrotic effect of the P2X7 receptor antagonist A740003 against acute myocardial infarction-induced fibrotic remodelling.

Almusallam N, Alonazi A, Bin Dayel A, Almubarak A, Ali R, Althakfi W Saudi Pharm J. 2024; 32(7):102102.

PMID: 39035363 PMC: 11258548. DOI: 10.1016/j.jsps.2024.102102.

Therapeutic potentials of allicin in cardiovascular disease: advances and future directions.

Gao Y, Wang B, Qin G, Liang S, Yin J, Jiang H Chin Med. 2024; 19(1):93.

PMID: 38956680 PMC: 11218272. DOI: 10.1186/s13020-024-00936-8.

References

Zhao L, Wang X, Chang Q, Xu J, Huang Y, Guo Q . Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis. Eur J Pharmacol. 2009; 627(1-3):304-12. DOI: 10.1016/j.ejphar.2009.11.007. View

Wang H, Jiang W, Hu Y, Wan Z, Bai H, Yang Q . Quercetin improves atrial fibrillation through inhibiting TGF-β/Smads pathway via promoting MiR-135b expression. Phytomedicine. 2021; 93:153774. DOI: 10.1016/j.phymed.2021.153774. View

Wang Q, Wei S, Li L, Bu Q, Zhou H, Su W . miR-139-5p sponged by LncRNA NEAT1 regulates liver fibrosis via targeting β-catenin/SOX9/TGF-β1 pathway. Cell Death Discov. 2021; 7(1):243. PMC: 8446030. DOI: 10.1038/s41420-021-00632-8. View

Li C, Li J, Xue K, Zhang J, Wang C, Zhang Q . MicroRNA-143-3p promotes human cardiac fibrosis via targeting sprouty3 after myocardial infarction. J Mol Cell Cardiol. 2019; 129:281-292. DOI: 10.1016/j.yjmcc.2019.03.005. View

Wang L, Jiang P, He Y, Hu H, Guo Y, Liu X . A novel mechanism of Smads/miR-675/TGFβR1 axis modulating the proliferation and remodeling of mouse cardiac fibroblasts. J Cell Physiol. 2019; 234(11):20275-20285. DOI: 10.1002/jcp.28628. View

Wang J, Xu N, Feng X, Hou N, Zhang J, Cheng X . Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure. Circ Res. 2005; 97(8):821-8. DOI: 10.1161/01.RES.0000185833.42544.06. View

Wei Y, Wu Y, Feng K, Zhao Y, Tao R, Xu H . Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-β/Smads pathway. J Ethnopharmacol. 2019; 249:112404. DOI: 10.1016/j.jep.2019.112404. View

Meng Q, Bhandary B, Bhuiyan M, James J, Osinska H, Valiente-Alandi I . Myofibroblast-Specific TGFβ Receptor II Signaling in the Fibrotic Response to Cardiac Myosin Binding Protein C-Induced Cardiomyopathy. Circ Res. 2018; 123(12):1285-1297. PMC: 6309316. DOI: 10.1161/CIRCRESAHA.118.313089. View

Zhao K, Mao Y, Ye X, Ma J, Sun L, Li P . MicroRNA-210-5p alleviates cardiac fibrosis via targeting transforming growth factor-beta type I receptor in rats on high sodium chloride (NaCl)-based diet. Eur J Pharmacol. 2021; 912:174587. DOI: 10.1016/j.ejphar.2021.174587. View

10.

Huang S, Chen B, Su Y, Alex L, Humeres C, Shinde A . Distinct roles of myofibroblast-specific Smad2 and Smad3 signaling in repair and remodeling of the infarcted heart. J Mol Cell Cardiol. 2019; 132:84-97. PMC: 6579679. DOI: 10.1016/j.yjmcc.2019.05.006. View

11.

Bian Z, Ji W, Xu B, Huo Z, Huang H, Huang J . Noncoding RNAs involved in the STAT3 pathway in glioma. Cancer Cell Int. 2021; 21(1):445. PMC: 8381529. DOI: 10.1186/s12935-021-02144-y. View

12.

Chakrabarti M, Al-Sammarraie N, Gebere M, Bhattacharya A, Chopra S, Johnson J . Transforming Growth Factor Beta3 is Required for Cardiovascular Development. J Cardiovasc Dev Dis. 2020; 7(2). PMC: 7344558. DOI: 10.3390/jcdd7020019. View

13.

Jiang L, Chen F, Zang S, Yang Q . Betulinic acid prevents high glucose‑induced expression of extracellular matrix protein in cardiac fibroblasts by inhibiting the TGF‑β1/Smad signaling pathway. Mol Med Rep. 2017; 16(5):6320-6325. DOI: 10.3892/mmr.2017.7323. View

14.

Liu L, Luo F, Lei K . Exosomes Containing LINC00636 Inhibit MAPK1 through the miR-450a-2-3p Overexpression in Human Pericardial Fluid and Improve Cardiac Fibrosis in Patients with Atrial Fibrillation. Mediators Inflamm. 2021; 2021:9960241. PMC: 8257384. DOI: 10.1155/2021/9960241. View

15.

Feng W, Ying Z, Ke F, Mei-Lin X . Apigenin suppresses TGF-β1-induced cardiac fibroblast differentiation and collagen synthesis through the downregulation of HIF-1α expression by miR-122-5p. Phytomedicine. 2021; 83:153481. DOI: 10.1016/j.phymed.2021.153481. View

16.

Yang X, Zhao Z . miR-30a-5p inhibits the proliferation and collagen formation of cardiac fibroblasts in diabetic cardiomyopathy. Can J Physiol Pharmacol. 2022; 100(2):167-175. DOI: 10.1139/cjpp-2021-0280. View

17.

Wu X, Zhu J, Wei Y, Guan X, Zhang Y, Chen W . MicroRNA-663 participates in myocardial fibrosis through interaction with TGF-β1. Exp Ther Med. 2019; 18(4):3172-3176. PMC: 6755453. DOI: 10.3892/etm.2019.7902. View

18.

Ni H, Li W, Zhuge Y, Xu S, Wang Y, Chen Y . Inhibition of circHIPK3 prevents angiotensin II-induced cardiac fibrosis by sponging miR-29b-3p. Int J Cardiol. 2019; 292:188-196. DOI: 10.1016/j.ijcard.2019.04.006. View

19.

Tao H, Zhang J, Qin R, Dai C, Shi P, Yang J . LncRNA GAS5 controls cardiac fibroblast activation and fibrosis by targeting miR-21 via PTEN/MMP-2 signaling pathway. Toxicology. 2017; 386:11-18. DOI: 10.1016/j.tox.2017.05.007. View

20.

Tao J, Wang J, Li C, Wang W, Yu H, Liu J . MiR-216a accelerates proliferation and fibrogenesis via targeting PTEN and SMAD7 in human cardiac fibroblasts. Cardiovasc Diagn Ther. 2020; 9(6):535-544. PMC: 6987511. DOI: 10.21037/cdt.2019.11.06. View